Scientific validity
Review whether the core claim is supported by credible validation, publications, benchmarks or reproducible evidence.
Sample AI Vendor Evaluation Dossier
A practical structure for independent AI vendor decisions.
TranslAItion Partners turns vendor claims, scientific evidence, data readiness and implementation risk into a clear dossier your team can use before a pilot, license decision or strategic partnership.
- Fictional sample structure
- No vendor promotion
- Decision-focused output
What it is
An evidence-led dossier before the decision becomes expensive.
The AI Vendor Evaluation Dossier is a concise decision-support document for biotech and pharma teams evaluating an AI platform. It is designed to clarify what is proven, what is assumed, what is missing and what would need to be tested before committing budget, data access or internal R&D capacity.
This page shows the type of structure and thinking a dossier can include. The example scenario is intentionally fictional and does not refer to any real AI vendor.
Evaluation criteria
The review connects scientific evidence to real adoption risk.
Biological fit
Assess whether the platform fits the disease area, modality, biological question and R&D decision workflow.
Data readiness
Clarify the data quality, annotation, volume, governance and format assumptions required for the platform to perform.
Implementation friction
Identify setup work, integrations, compliance review, team handover and adoption effort before the pilot starts.
Cost-to-outcome value
Compare license costs, hidden dependencies and team time with realistic scientific or strategic outcomes.
Decision recommendation
Summarize whether to proceed, pause, redesign the pilot or request stronger evidence before committing.
Fictional example
Sample scenario: AI biomarker discovery platform.
A pharma R&D team is considering an AI platform that claims to identify clinically relevant biomarkers in immuno-oncology using multi-omics data. The team needs to know whether the vendor's validation evidence, data assumptions and workflow fit justify a pilot or licensing discussion.
Claim
The vendor claims faster biomarker discovery and improved patient stratification.
Evidence
The dossier reviews validation material, benchmark relevance and what has not been independently tested.
Fit
The platform is mapped against therapeutic context, available data and internal R&D workflows.
Decision
The output defines pilot conditions, go/no-go criteria and the remaining risks.
Dossier structure
What the output can include.
Summary
Executive decision brief
A concise summary of the decision context, main risks, evidence strength and recommended next step.
Claims
Vendor claim review
A structured review of the vendor's scientific, operational and commercial claims, separated from marketing language.
Evidence
Validation and evidence check
Assessment of publications, benchmark data, validation scope, reproducibility signals and missing proof points.
Fit
Workflow and data fit
Mapping of the platform against the team's therapeutic question, data environment, governance and adoption path.
Risk
Risk register and pilot criteria
Clear risks, unresolved questions and go/no-go criteria for any pilot, partnership or procurement step.
How teams use it
Built for decisions, not document volume.
The dossier gives scientific, innovation, procurement and leadership stakeholders a shared view of the evidence and trade-offs. It can support vendor shortlisting, pilot design, license discussions, partnership review or internal investment decisions.
Before a pilot
Define what should be tested, which proof points matter and what success should mean before the pilot starts.
Before selection
Compare shortlisted platforms against the same scientific, operational and value criteria.
Before scaling
Check whether promising early results can survive broader adoption, larger datasets and real workflow constraints.
Want this structure applied to your AI vendor decision?
Share the vendor, platform category or AI use case you are evaluating. We will help clarify what evidence, risks and pilot criteria need to be reviewed.
All conversations are confidential. We respond within 24 hours.